Cost-effectiveness analysis of thoracic radiotherapy in non-operated clinical stage IIIA non-small cell lung cancer

被引：0
|
作者：
Chien, C. R. [1 ,2 ]
Wang, P. H. [3 ]
机构：
[1] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan
[2] Ctr Canc, Taichung, Taiwan
[3] China Med Univ Hosp, Dept Canc Ctr, Taichung, Taiwan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3437
引用
收藏
页码：S807 / S808
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer
    Czarnecka-Kujawa, Katarzyna
    Rochau, Ursula
    Siebert, Uwe
    Atenafu, Eshetu
    Darling, Gail
    Waddell, Thomas Kenneth
    Pierre, Andrew
    De Perrot, Marc
    Cypel, Marcelo
    Keshavjee, Shaf
    Yasufuku, Kazuhiro
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 153 (06): : 1567 - 1576
  • [42] Cost-Effectiveness of Hybrid PET/CT for Staging of Non-Small Cell Lung Cancer
    Schreyoegg, Jonas
    Weller, Julia
    Stargardt, Tom
    Herrmann, Ken
    Bluemel, Christina
    Dechow, Tobias
    Glatting, Gerhard
    Krause, Bernd J.
    Mottaghy, Felix
    Reske, Sven N.
    Buck, Andreas K.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (11) : 1668 - 1675
  • [43] COST-EFFECTIVENESS OF MULTIPLEXED PREDICTIVE BIOMARKER SCREENING IN NON-SMALL CELL LUNG CANCER
    Romanus, D.
    Cardarella, S.
    Cutler, D.
    Landrum, M. B.
    Lindeman, N.
    Gazelle, G. S.
    VALUE IN HEALTH, 2015, 18 (03) : A204 - A204
  • [44] A REVIEW OF COST-EFFECTIVENESS STUDIES OF PEMBROLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Qiao, N.
    Insinga, R.
    Burke, T.
    Lopes, G.
    VALUE IN HEALTH, 2020, 23 : S41 - S42
  • [45] Pneumonectomy for Clinical Stage IIIA Non-Small Cell Lung Cancer: The Effect of Neoadjuvant Therapy
    Broderick, Stephen R.
    Patel, Aalok P.
    Crabtree, Traves D.
    Bell, Jennifer M.
    Morgansztern, Daniel
    Robinson, Clifford G.
    Kreisel, Daniel
    Krupnick, A. Sasha
    Patterson, G. Alexander
    Meyers, Bryan F.
    Puri, Varun
    ANNALS OF THORACIC SURGERY, 2016, 101 (02): : 451 - 458
  • [46] Comparing the cost-effectiveness of perioperative immunotherapy strategies in non-small cell lung cancer
    Muthusamy, B.
    Zabor, E. C.
    Pennell, N. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S743 - S743
  • [47] Evaluation of Cost-effectiveness of FDG-PET in Non-Small Cell Lung Cancer
    Hoekstra, Otto S.
    van Tinteren, Harm
    Smit, Egbert F.
    PET CLINICS, 2006, 1 (04) : 329 - +
  • [48] Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
    Pavlakis, N
    Mitchell, PL
    Slynes, G
    Aristides, M
    Davey, P
    Rajan, N
    Arora, B
    Liepa, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 549S - 549S
  • [49] Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer
    Szczepura, A
    LUNG CANCER, 2002, 38 : S21 - S28
  • [50] Cost-effectiveness models of non-small cell lung cancer: A systematic literature review
    Willis, Michael
    Nilsson, Andreas
    Lwin, Zin Min Thet
    Bradvik, Gunnar
    Prelaj, Arsela
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01): : 69 - 81
12345